

Supplementary Table I. Efficacy at Weeks 12 and 24<sup>β,Ω</sup>

	Week 12			Week 24		
	PBO N=118	IXEQ4W N=122	IXEQ2W N=123	PBO N=118	IXEQ4W N=122	IXEQ2W N=123
SF-36 PCS <sup>§</sup>	2.7 (1.1) <sup>§</sup>	7.1 (1.1)*	7.2 (1.0)*	3.3 (1.4)	8.9 (1.3)*	8.2 (1.2)*
SF-36 MCS <sup>§</sup>	-1.2 (1.2)	3.1 (1.2)*	3.2 (1.1)*	0.9 (1.3)	3.6 (1.2) <sup>¶</sup>	4.0 (1.2) <sup>¶</sup>
<i>SF-36 Domains</i>						
Physical functioning	5.3 (2.7)	17.8 (2.7)*	15.8 (2.6)*	8.6 (3.3)	24.9 (3.1)*	19.8 (3.0)*
Role physical	9.5 (3.2)	21.4 (3.2)*	22.7 (3.1)*	8.6 (3.9)	21.3 (3.7)*	23.7 (3.5)*
Bodily pain	5.3 (2.9)	17.7 (2.8)*	18.4 (2.7)*	11.4 (3.5)	25.3 (3.3)*	23.0 (3.2)*
General health	-0.6 (2.1)	8.2 (2.0)*	8.0 (2.0)*	-0.7 (2.5)	7.9 (2.4)*	7.9 (2.3)*
Vitality	0.7 (2.5)	10.5 (2.5)*	12.1 (2.4)*	5.5 (3.2)	14.4 (3.0) <sup>†</sup>	16.4 (2.9)*
Social functioning	3.4 (2.9)	15.9 (2.9)*	15.5 (2.8)*	11.6 (3.6)	18.2 (3.3) <sup>¶</sup>	18.7 (3.2) <sup>¶</sup>
Role emotional	-0.5 (2.9)	11.3 (2.8)*	11.6 (2.7)*	1.0 (3.2)	13.4 (3.0)*	11.5 (2.8)*
Mental health	-1.8 (2.2)	6.0 (2.2)*	5.2 (2.1)*	2.0 (2.5)	7.5 (2.4) <sup>¶</sup>	7.8 (2.3) <sup>¶</sup>
EQ-5D VAS	-0.5 (3.0)	12.6 (2.9)*	12.0 (2.8)*	1.8 (3.4)	15.3 (3.2)*	12.8 (3.0)*
Joint pain VAS <sup>§</sup>	-11.9 (3.4)	-29.8 (3.3)*	-27.0 (3.2)*	-21.4 (4.0)	-36.9 (3.7)*	-33.5 (3.6)*
PtGA VAS <sup>§</sup>	-10.7 (3.4)	-34.5 (3.4)*	-32.9 (3.2)*	-19.0 (3.9)	-40.7 (3.7)*	-37.3 (3.5)*
BASDAI <sup>§</sup>	-1.2 (0.3)	-2.8 (0.3)*	-2.6 (0.3)*	-2.1 (0.4)	-3.7 (0.4)*	-3.6 (0.4)*
BASDAI- Neck, back, or hip pain**	-1.3 (0.4)	-2.1 (0.4) <sup>¶</sup>	-2.3 (0.4) <sup>†</sup>	-2.3 (0.6)	-3.3 (0.6) <sup>¶</sup>	-3.3 (0.5) <sup>¶</sup>
<i>WPAI-SHP</i>						
% absenteeism	6.1 (4.4)	4.6 (4.4)	3.7 (4.2)	4.5 (5.0)	3.7 (4.6)	9.4 (4.4)
% presenteeism	-3.4 (3.6)	-23.3 (3.5)*	-20.5 (3.4)*	-7.2 (4.9)	-26.6 (4.3)*	-24.0 (4.1)*
% activity impairment	-6.1 (3.2)	-24.9 (3.2)*	-20.9 (3.1)*	-14.8 (4.1)	-30.2 (3.9)*	-26.2 (3.7) <sup>†</sup>
% overall work impairment	-1.2 (4.3)	-19.7 (4.1)*	-18.2 (4.0)*	-4.5 (5.4)	-23.2 (4.7)*	-17.6 (4.6) <sup>¶</sup>
DLQI <sup>‡</sup>	-1.5 (0.8)	-6.9 (0.8)*	-5.7 (0.8)*	-3.1 (0.9)	-7.7 (0.8)*	-7.3 (0.8)*
DLQI (0/1), % <sup>‡</sup>	13.4	61.8*	44.1*	9.0	51.5*	50.0*
Itch NRS <sup>‡</sup>	-0.7 (0.4)	-3.4 (0.4)*	-3.3 (0.4)*	-1.2 (0.5)	-3.4 (0.4)*	-3.5 (0.4)*
Itch NRS=0, % <sup>‡</sup>	0	29.4*	22.1*	0	23.5*	23.5*

Note: \* $p \leq 0.001$  active vs. PBO; <sup>†</sup> $p \leq 0.005$  active vs. PBO; <sup>¶</sup> $p \leq 0.05$  active vs. PBO

<sup>β</sup>For continuous outcome, treatment comparison was made using MMRM. LS mean change from baseline and SE are shown.

<sup>Ω</sup>For categorical outcome, treatment comparison was made using logistic model with missing values imputed by NRI.


<sup>§</sup>Data from Nash *et al.* (16).

<sup>§</sup>Evaluated among ITT patients with baseline BASDAI >4. N=96, N=100, and N=99 for PBO, IXEQ4W, and IXEQ2W, respectively.

\*\*Among patients with baseline BASDAI Individual Component #2 (neck, back, or hip pain) Score >4.

<sup>‡</sup>Evaluated among ITT patients with psoriatic lesions involving  $\geq 3\%$  of the body surface area. N=67, N=68, and N=68 for PBO, IXEQ4W, and IXEQ2W, respectively.


BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; DLQI: Dermatology Life Quality Index; EQ-5D: European Quality of Life-5 Dimensions 5 Level; ITT: intent-to-treat; IXEQ2W: ixekizumab 80 mg every 2 weeks; IXEQ4W: ixekizumab 80 mg every 4 weeks; LS mean: least squares mean; MCS: Mental Component Summary; MMRM: mixed models repeated measures analysis; N: population size; NRI: non-responder imputation; NRS: Numeric Rating scale; PCS: Physical Component Summary; PBO: placebo; PtGA, Patient Global Assessment; SE: standard error; SF-36: 36-Item Short Form Health Survey; VAS: visual analogue scale; WPAI-SHP: Work Productivity and Activity Impairment-Specific Health Problem.



**Supplementary Fig. 1.** Study Design.

This study used the ITT population, defined as all randomised patients and analysed according to their assigned treatment. After Week 24, outcomes are reported only for patients originally assigned to ixekizumab.

ITT: intent-to-treat; IR: inadequate responders; IXEQ2W: ixekizumab 80 mg every 2 weeks; IXEQ4W: ixekizumab 80 mg over 4 weeks; N: population size; PBO: placebo; R: randomisation; RT: rescue therapy. <sup>a</sup>Plus RT in inadequate responders.



**Supplementary Fig. 2.** BASDAI.

The graph shows the BASDAI to Week 24 in the intent-to-treat population with baseline BASDAI >4. Observed data at Week 24 for Week 16 inadequate responders were excluded. LS mean change from baseline is reported and based on an MMRM model.

\*  $p \leq 0.001$  active vs. PBO.

BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; IXEQ2W: ixekizumab 80 mg every 2 weeks; IXEQ4W: ixekizumab 80 mg every 4 weeks; LS mean: least squares mean; MMRM: mixed models repeated measures analysis; N: population size; PBO: placebo.